Health
The Health Section develops policy positions that promote biomedical innovation and represent the best interests of BIO member companies with a direct interest in human health. Among the priority issues the Health Section focuses on are matters affecting the healthcare-related regulatory and reimbursement climate, pandemic and biodefense preparedness, publicly-funded scientific research, and personalized medicine. The Health Section is managed by a Section governing body and recommends members to sit on BIO's Board of Directors.
Staff Contact: Kay Holcombe
Ron Cohen, MD, Chair
Acorda Therapeutics, Inc
Paul J. Hastings, Vice Chair
OncoMed Pharmaceuticals, Inc
Rachel K. King, Immediate Past Chair
GlycoMimetics, Inc
Kristine Peterson, Secretary
Valeritas, Inc
Daniel Apel
Bayer Healthcare LLC
Stuart A. Arbuckle
Vertex Pharmaceuticals Incorporated
Alex M. Azar II
Eli Lilly and Company
Jean-Jacques Bienaimé
BioMarin Pharmaceutical, Inc
Ian T. Clark
Roche
Stanley T. Crooke, MD, PhD
Isis Pharmaceuticals, Inc
John F. Crowley, JD, MBA
Amicus Therapeutics, Inc
Douglas A. Doerfler
MaxCyte, Inc
Deborah Dunsire, MD
FORUM Pharmaceuticals Inc
Paul R. Eisenberg, MD, MPH
Amgen Inc.
Mark Enyedy
Shire
William Fitzsimmons, PharmD, MS
Astellas Pharma US
Julie L. Gerberding, MD, MPH
Merck & Co, Inc
Geno Germano
Pfizer Inc
John Glasspool
Baxalta
Glenn Gormley, MD, PhD
Daiichi Sankyo Pharma Development
Maxine Gowen, PhD
Trevena, Inc.
Peter S. Greenleaf
Sucampo Pharmaceuticals, Inc
David Hallal
Alexion Pharmaceuticals, Inc
Russell H. Herndon
Hydra Biosciences, Inc
Steven H. Holtzman
Biogen
Hervé Hoppenot
Incyte Corporation
Paul Hudson
AstraZeneca, Plc
Daniel M. Junius
ImmunoGen, Inc
Perry Karsen
Celgene Corporation
Scott Koenig, MD, PhD
MacroGenics, Inc
Nick Leschly
bluebird bio
Sabine Luik, MD, MPH
Boehringer Ingelheim Pharmaceuticals, Inc.
John Maraganore, PhD
Alnylam Pharmaceuticals, Inc
Thomas P. Mathers
CoLucid Pharmaceuticals, Inc
David P. Meeker, MD
Genzyme Corporation, A Sanofi Company
Steven J. Mento, PhD
Conatus Pharmaceuticals, Inc
John F. Milligan, PhD
Gilead Sciences, Inc
Michael Narachi
Orexigen Therapeutics, Inc
John A. Orwin
Relypsa, Inc
Paris Panayiotopoulos
EMD Serono, Inc
Adelene Q. Perkins
Infinity Pharmaceuticals, Inc.
Richard Pops
Alkermes, Inc.
Robert Repella
CSL Behring
Howard W. Robin
Nektar Therapeutics, Inc
Timothy C. Rodell, M.D.
GlobeImmune, Inc.
Raymond Sacchetti
Bristol-Myers Squibb
David Schenkein, MD
Agios Pharmaceuticals, Inc
Michael Severino, MD
AbbVie Inc.
Christi L. Shaw
Novartis Pharmaceuticals Corporation
Jay P. Siegel, MD
Johnson & Johnson
Mark Skaletsky
Fenway Pharmaceuticals, Inc
Moncef Slaoui, PhD
GSK
David M. Stack
Pacira Pharmaceuticals, Inc.
Henri A. Termeer
AVEO Pharmaceuticals, Inc.
Mark Timney
Purdue Pharma LP
Gil Van Bokkelen, PhD
Athersys, Inc
Harold E. Van Wart, PhD
CymaBay Therapeutics
H. Thomas Watkins, Immediate Past Chair
Chair Emeritus, BIO
Allen Waxman
Eisai, Inc.
Edward Williams
Novo Nordisk
Rick E. Winningham
Theravance Biopharma US, Inc.
Jeffrey Wren
UCB, Inc